Search
Now showing items 1-10 of 12
Evaluation of antibody response in symptomatic and asymptomatic covid-19 patients and diagnostic assessment of new IgM/IgG elisa kits
(
MDPI
, 2021 , Article)
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This study aims to study the immune response and evaluate the performances of four new IgM and five IgG enzyme-linked immunosorbent assay (ELISA) kits for detecting ...
Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months
(
Elsevier
, 2021 , Article)
We document two cases of viremic and prolonged active infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) where the viral genome was conserved for two months, but infection was with little or ...
SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals
(
Elsevier
, 2021 , Article)
The study objective was to the assess level of detectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in the urban population of Qatar. Antibody testing was performed on residual blood specimens ...
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
(2021 , Article)
The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna) vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-19 due to infection with ‘wild-type’ variants in a ...
Effect of multiple freeze–thaw cycles on the detection of anti-SARS- CoV- 2 IgG antibodies
(
Microbiology Society
, 2021 , Article)
Several studies have investigated the effect of repeated freeze-thaw (F/T) cycles on RNA detection for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). However, no data are available regarding the effect of ...
Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: Mathematical modelling analyses
(
BMJ Publishing Group
, 2021 , Article)
Background Vaccines against SARS-CoV-2 have been developed, but their availability falls far short of global needs. This study aimed to investigate the impact of prioritising available doses on the basis of recipient ...
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy
(
Elsevier
, 2021 , Article)
Background Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been documented, raising public health concerns. SARS-CoV-2 reinfections were assessed in a cohort of antibody-positive persons ...
Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting
(
NLM (Medline)
, 2021 , Article)
BACKGROUND: Risk of reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown. We assessed the risk and incidence rate of documented SARS-CoV-2 reinfection in a cohort of laboratory-confirmed ...
Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses.
(
Oxford University Press
, 2021 , Article)
Strategies for rolling out vaccination against Coronavirus Disease 2019 (Covid-19) varied across countries. A key question is whether delaying administration of the second vaccine dose to vaccinate the largest number of ...
Epidemiology of SARS-CoV2 in Qatar's primary care population aged 10 years and above
(
BMC
, 2021 , Article)
There is an urgent need to elucidate the epidemiology of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) and characterize its potential impact. Investing in characterising the SARS-CoV2 will help plan and ...